The objective is to improve the management of haemorrhagic syndrome due to viper envenomation in sub-Saharan Africa through symptomatic treatment. The hemorrhagic syndrome is frequently complicated by the persistence of bleeding – or its recurrence – several days after the administration of a correct dose of antivenom.
We formulate the hypothesis that the persistence of bleeding despite the antivenom results from secondary hyperfibrinolysis (destruction of the clot as it forms) in relation to an uncontrolled defense mechanism of the organism.
The study will take place in two phases.
- The first (August-November 2022) is observational and will consist of analyzing the evolution of the haemorrhagic syndrome in patients treated with antivenom (standard protocol) to confirm our hypothesis.
- During the second period (May-October 2023), we will carry out a randomized clinical trial with two arms: antivenom alone versus antivenom + antifibrinolytic administered systematically in all patients with bleeding.
The decision criteria will be a) the rapidity of the cessation of bleeding and b) the total quantity of antivenom administered to the patients in each of the groups.
Northern Partnership
Southern Partnership
IRCB
Calendar
2022/2023
